

**Maricopa Integrated Health Systems
Formulary Prior Auth Criteria**

Drug: Neupogen (Filgrastim)/Neulasta (Pegfilgrastim)

Therapy:

- A) Patients receiving myelosuppressive chemotherapy- decrease incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy associated with a significant incidence of severe neutropenia with fever.
- B) Acute Myeloid Leukemia (AML) receiving induction or consolidation chemotherapy- reduce time to neutrophil recovery and the duration of fever
- C) Patients receiving Bone Marrow Transplant (BMT)- to reduce duration of neutropenia and neutropenia related clinical sequelae in patients undergoing myeloblastic chemotherapy followed by marrow transplantation
- D) Patients with Severe Chronic Neutropenia (SCN)- chronic administration to reduce the incidence and duration of sequelae of neutropenia in symptomatic patients with congenital neutropenia, cyclic neutropenia or idiopathic neutropenia
- E) Patient undergoing Peripheral Blood Progenitor Cell (PBPC) Collection- mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. Mobilization allows for collection of increased numbers of progenitor cells capable of engraftment, which in turn can lead to more rapid engraftment

Inclusions:

- A) Request needs to come from an Oncologist or HIV doctor
- B) Patient has a diagnosis of neutropenia or is at risk for developing neutropenia
- C) CBC with dif
- D) Length of chemotherapy
- E) Stem cell collection preparation

Contraindications:

Use of Neupogen in patients with known hypersensitivity to *E coli*-derived proteins, Neupogen, or any other component is contraindicated.

Precautions

Simultaneous use with chemotherapy and radiation therapy-

- 1) Do not use 24 hours before through 24 hours after the administration of cytotoxic chemotherapy.
- 2) Simultaneous use should be avoided; safety and efficacy of Neupogen with concurrent radiation and chemotherapy have not been established

Authorization:

Oncology-

Length of chemotherapy

HIV-

Three months then six months increments with documented efficacy and CBC with dif

Stem cell collection

Six months

Medical Director_____

Date_____